Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Cancer Immunol Res. 2016 Feb 12;4(4):345–353. doi: 10.1158/2326-6066.CIR-15-0193

Figure 3.

Figure 3

Kaplan-Meyer plot comparison of cohorts 1-2-3 to cohorts 4-5-6 of the 92 ipilimumab-refractory patients receiving nivolumab. A, Months of progression-free survival and. B, length of overall survival. P values determined by log-rank test. Data for each cohort displayed beneath each plot